Jazz los­es ap­peal, will have patent delist­ed from the Or­ange Book

The US Court of Ap­peals for the Fed­er­al Cir­cuit is up­hold­ing an in­junc­tion that states that a patent re­lat­ed to Jazz Phar­ma­ceu­ti­cals’ nar­colep­sy drug should be delist­ed from the FDA’s gener­ic drug com­pendi­um known as the Or­ange Book.

The patent in ques­tion, called the ‘963 patent, is re­lat­ed to Jazz’s “sin­gle-phar­ma­cy dis­tri­b­u­tion sys­tem” which is de­signed to con­trol ac­cess to drugs pre­scribed to nar­colep­sy pa­tients, which can be abused. The patents in­clude a cen­tral phar­ma­cy and com­put­er data­base that can track pre­scrip­tions and pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER